Trial of a Blink-assisted Eyelid Device in Treating the Sign
The clinical characteristics of meibomian gland disease include decreased stability of tear films, damage in the eye surface, eye irritation sensations and visual variations. Adequate treatment is essential to treat people with dry-eye illness caused by meibomian glandular disease to reduce the signs and symptoms of a patient.

The purpose of this analysis was to determine whether the controlled heating of meibomian glands with the SmartLid devices (TearCare) combined with evacuation of the liquefied meibum using a handheld clearance assistant would improve a patient's dry eye symptoms and signs.

This study involved a retrospective analysis of data gathered in a single-center ophthalmology/optometry practice. The symptom frequency and severity were assessed using the SPEED questionnaire, and the signs were assessed via MGE scores before and after (8 to 12 weeks) treatment. A further analysis evaluating efficacy in subgroups based on age, race, and sex was performed. A statistical analysis was performed with t tests for group comparisons.

--A SPEED questionnaire was answered by 92 patients with dry eye disease.

--In addition, each patient's meibomian gland function was recorded as MGE scores for each eye (176 eyes).

--These procedures were completed before and approximately 8 weeks after a single bilateral TearCare treatment.

--The median total SPEED score was reduced from 16 to 9, and the total MGE scores improved from 5.0 to 9.0 in the right eye and 4.0 to 9.0 in the left eye after a single TearCare treatment.

Conclusively, a single TearCare treatment was effective in reducing both the signs and symptoms of dry eye in all subjects.